Moreover, it provides one possible explanation for the lack of efficacy of helminth-therapy in recent IBD trials, such that patients who lack SCFA-producing bacteria [51], lack butyrate transporters or receptors [52], or with a diminished capacity to express il-10 or the il-10-receptor [53] would be contraindicated for this novel treatment. Here, IL10 is linked to inflammatory bowel disease.